Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

2 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Assessment of Suspected Pulmonary Embolism

- 06-11-18 - 1 Formulier, 9 Itemgroepen, 32 Data-elementen, 1 Taal
Itemgroepen: Pulmonary Embolism, Suspicion, Pulmonary Embolism; Lung Scan, Ultrasonography, Venography, Angiogram, Tomography, Spiral Computed, Other Tests, Therapeutic Procedure, Pulmonary Embolism, Seriousness
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Eligibility NCT00439725 Deep Vein Thrombosis - Eligibility

- 09-12-13 - 1 Formulier, 3 Itemgroepen, 17 Data-elementen, 2 Talen
Itemgroepen: Inclusion criteria, Exclusion criteria, Medical Concepts
This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT or PE who completed 6 or 12 months of treatment with rivaroxaban or VKA are eligible for this trial (Einstein-Extension study).

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial